Asset profile
zasocitinib
Small molecule
Evidence outlook · lead readout
NCT06973291 · Plaque Psoriasis
The completed lead evidence has the design features that historically survive confirmatory trials: randomized, controlled, and adequately powered against a prespecified clinically accepted endpoint.
NCT06973291: This Phase 3 trial was randomized and double-blind, comparing zasocitinib directly against an active comparator (deucravacitinib) in 606 adults with plaque psoriasis. Its primary endpoint, complete skin clearance (PASI-100) at Week 16, was met: more than 35% of zasocitinib-treated patients achieved complete clearance, over 2.5 times the rate seen with deucravacitinib.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Also in development:Psoriatic Arthritis · Phase 3
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
92 competitors in this universe: 10 direct rivals (same mechanism and indication), 2 same-class, 80 same-indication; 48 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Zasocitinib: this drug | Phase 3 | Small molecule | TYK2 | ||
| Deucravacitinib (Sotyktu) | Approved | Small molecule | TYK2 | ||
| Envudeucitinib | Phase 3 | Small molecule | TYK2 | ||
| HS-10374 | Phase 3 | Small molecule | TYK2 | ||
| ICP-488 | Phase 3 | Small molecule | TYK2 | ||
| SYHX1901 | Phase 3 | Small molecule | TYK2 | ||
| TQH3906 | Phase 3 | Small molecule | TYK2 | ||
| WD-890 | Phase 3 | Small molecule | TYK2 | ||
| CMS-D001 | Phase 2/3 | Small molecule | TYK2 | ||
| BMS-986322 | Phase 2 | Small molecule | TYK2 | ||
| CS32582 | Phase 1/2 | Small molecule | TYK2 | ||
| D-2570 | Phase 3 | Small molecule | TYK2 | ||
| GLPG3667 | Phase 2 | Small molecule | TYK2 | ||
| Abatacept (Orencia) | Approved | Protein / enzyme therapeutic | CD80/CD86 (CTLA-4-Ig), Selective T Cell Costimulation Modulator, CD80/CD86 (B7-1/B7-2) on antigen-presenting cells | ||
| Adalimumab (Humira) | Approved | Monoclonal antibody | TNF-alpha | ||
| Adalimumab-Aacf (Idacio) | Approved | — | TNF-alpha |
…and 77 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
4 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(11 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (5)
February 2027 (1)
What to watch
May 2027 (3)
What to watch
What to watch
What to watch
October 2027 (1)
What to watch
2028 (2)
2029 (3)
August 2029 (1)
What to watch
2033 (1)
January 2033 (1)
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.